文献速递基础与转化研究临床试验与 GCP

慢病毒基因治疗联合低剂量白消安治疗SCID-X1婴儿

Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
PubMed 文献 · N Engl J Med · 2019-01-01

这项双中心1-2期研究对8例新诊断SCID-X1婴儿,在低暴露靶向白消安预处理后,用慢病毒载体将IL2RG cDNA转入骨髓干细胞。中位随访16.4个月,7例T细胞、NK细胞于输注后3-4个月恢复正常,1例经无白消安二次输注后T细胞恢复;所有婴儿感染清除、生长正常;7例IgM正常,其中4例停用静脉免疫球蛋白,3例对疫苗有应答;载体插入位点分析7例均为多克隆模式、无克隆优势。

要点

  • 慢病毒基因治疗联合低暴露靶向白消安在8例新诊断SCID-X1婴儿中急性毒性低。
  • 7例婴儿CD3+、CD4+、初始CD4+ T细胞及NK细胞在输注后3-4个月恢复正常。
  • 第8例婴儿经无白消安预处理的基因校正细胞二次输注后T细胞发育。

核心结论

  • 慢病毒载体基因治疗联合低暴露靶向白消安预处理在新诊断SCID-X1婴儿中急性毒性低,中位随访16个月实现多系转导细胞植入、功能性T细胞和B细胞重建及NK细胞计数正常化。

研究设计与样本

  • 双中心1-2期安全性和有效性研究,纳入8例新诊断SCID-X1婴儿,在低暴露靶向白消安预处理后,用慢病毒载体将IL2RG互补DNA转入骨髓干细胞。

主要发现

  • 8例婴儿中位随访16.4个月;骨髓采集、白消安预处理和细胞输注均无意外副作用。
  • 7例婴儿CD3+、CD4+、初始CD4+ T细胞及NK细胞在输注后3-4个月恢复正常,伴T细胞、B细胞、NK细胞、髓系细胞和骨髓祖细胞载体标记。
  • 第8例婴儿初始T细胞计数不足,经无白消安预处理的基因校正细胞二次输注后T细胞发育。
  • 所有婴儿既往感染清除、生长正常;8例中7例IgM水平正常,其中4例停用静脉免疫球蛋白补充,这4例中3例对疫苗有应答。
  • 7例婴儿载体插入位点分析均显示多克隆模式、无克隆优势。

局限性

  • 中位随访16.4个月,为1-2期研究、样本量为8例婴儿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails to reconstitute immunity associated with T cells, B cells, and natural killer (NK) cells when matched sibling donors are unavailable unless high-dose chemotherapy is given. In previous studies, autologous gene therapy with γ-retroviral vectors failed to reconstitute B-cell and NK-cell immunity and was complicated by vector-related leukemia. METHODS: We performed a dual-center, phase 1-2 safety and efficacy study of a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells after low-exposure, targeted busulfan conditioning in eight infants with newly diagnosed SCID-X1. RESULTS: Eight infants with SCID-X1 were followed for a median of 16.4 months. Bone marrow harvest, busulfan conditioning, and cell infusion had no unexpected side effects. In seven infants, the numbers of CD3+, CD4+, and naive CD4+ T cells and NK cells normalized by 3 to 4 months after infusion and were accompanied by vector marking in T cells, B cells, NK cells, myeloid cells, and bone marrow progenitors. The eighth infant had an insufficient T-cell count initially, but T cells developed in this infant after a boost of gene-corrected cells without busulfan conditioning. Previous infections cleared in all infants, and all continued to grow normally. IgM levels normalized in seven of the eight infants, of whom four discontinued intravenous immune globulin supplementation; three of these four infants had a response to vaccines. Vector insertion-site analysis was performed in seven infants and showed polyclonal patterns without clonal dominance in all seven. CONCLUSIONS: Lentiviral vector gene therapy combined with low-exposure, targeted busulfan conditioning in infants with newly diagnosed SCID-X1 had low-grade acute toxic effects and resulted in multilineage engraftment of transduced cells, reconstitution of functional T cells and B cells, and normalization of NK-cell counts during a median follow-up of 16 months. (Funded by the American Lebanese Syrian Associated Charities and others; LVXSCID-ND ClinicalTrials.gov number, NCT01512888.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Mamcarz E, Zhou S, Lockey T, et al. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019. PMID: 30995372. doi:10.1056/NEJMoa1815408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。